Mark J. Carrico has joined Salt Lake City-based OrthoGrid Systems, Inc., and is occupying the newly created position of Director of Marketing.
“Mark brings a wealth of orthopedic experience to OrthoGrid, and his hands-on leadership style in combination with his proven history of executing value-creating customer programs makes him an excellent fit for our company,” noted Richard Boddington, OrthoGrid CEO, in the March 13, 2017 news release. “Mark will immediately contribute to OrthoGrid’s HipGrid commercialization activities and he will also begin to develop actionable marketing priorities for our orthopedic imaging and guidance R&D [research and development] pipeline. I am confident that Mark will deliver tremendous value at a very exciting time for OrthoGrid.”
As indicated in the news release, “Mark joins OrthoGrid from DePuy Synthes, a division of Johnson & Johnson, where he spent seven years leading the company’s Hip Replacement surgical approach marketing activities across the USA. Prior to DePuy, Mark enjoyed a successful career with Warner-Chilcott Pharmaceuticals and Organon Pharmaceuticals. Mark earned his BA degree in Economics from Indiana University.”
Carrico told OTW, “OrthoGrid’s portfolio of procedure-enabling technologies transcends the entire orthopedic spectrum and can bring tremendous value to surgeons and patients alike. I am energized to be joining OrthoGrid at a key point in the company’s growth cycle and will immediately begin leading our global efforts to raise awareness around how our value-creating products such as the patented HipGrid Drone can influence outcomes and patient reported satisfaction.”
“OrthoGrid owns a unique space in orthopedic imaging that is focused on simplicity and reproducibility, whereas competing technologies often have high upfront costs and require surgeons to change their procedural flow. So my first step as Director of Marketing is to help our prospective customers understand the clear benefits of OrthoGrid’s technology while ensuring that we continue to make evaluations & trial periods easy and without financial obligation.”
